Indication.Bio

Innovation is at the heart of everything we do at Indication Bioscience. Our mission is to redefine possibilities in cardiovascular care by developing therapies that address critical unmet needs, such as improving adherence for patients with statin intolerance. Through a science-driven approach and the integration of advanced technologies like proteomics, we are unlocking new ways to enhance treatment outcomes. With a focus on leveraging proven compounds and accelerated pathways, we are committed to delivering groundbreaking solutions that improve lives and transform patient care.

At Indication Bioscience, we collaborate with world-class clinical research organizations and healthcare innovators to accelerate the development of transformative therapies. By partnering with leaders like Target Health, Novotech and Nucleus Network, we ensure our clinical trials are conducted with precision and excellence. Together, we’re advancing Atorvo+ and other groundbreaking solutions to address critical challenges in cardiovascular care, setting new standards for innovation and patient outcomes.

Indication Bioscience was founded to solve one of the most pressing challenges in cardiovascular care: ensuring patients have access to therapies that work without compromising quality of life. Our journey began with the bold idea of combining statins with novel compounds to create therapies that improve adherence while maintaining efficacy. Today, with innovative programs like Atorvo+ and a world-class team of experts, we are well on our way to making this vision a reality.